---
layout: post
title: "火力全开 医药股全线爆发 业绩高增标的名单曝光"
date: 2022-03-10 18:02:10 +0800
categories: emnews
tags: 东财滚动新闻
---
> 今天大盘三大指数大幅高开，全天维持高位震荡，午后稍有回落。光伏、锂电等新能源方向走强，白银、黄金、有色锌、油服等板块逆市下跌。医药股成今天盘面上最靓的仔，涨幅居前的概念板块中，多数是医药细分概念，新冠检测板块午后拉升，兰卫医学、万孚生物、广生堂、明德生物等多股涨逾10%。（证券时报）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/90.BK1042" data-code="BK1042|90|1" data-code2="BK1042|90|2|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=90.BK1042&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 BK1042_0" data-code="K BK1042|90|1" data-code2="K BK1042|90|2|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>医药股成最亮眼的仔，机构认为<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>高增标的后市值得期待。<br /></p><p><strong>今天大盘三大指数大幅高开，全天维持高位震荡，午后稍有回落。光伏、锂电等新能源方向走强，白银、黄金、有色锌、油服等板块逆市下跌。</strong>医药股成今天盘面上最靓的仔，涨幅居前的概念板块中，多数是医药细分概念，新冠检测板块午后拉升，<span id="stock_0.301060"><a href="http://quote.eastmoney.com/unify/r/0.301060" class="keytip" data-code="0,301060">兰卫医学</a></span><span id="quote_0.301060"></span>、<span id="stock_0.300482"><a href="http://quote.eastmoney.com/unify/r/0.300482" class="keytip" data-code="0,300482">万孚生物</a></span><span id="quote_0.300482"></span>、<span id="stock_0.300436"><a href="http://quote.eastmoney.com/unify/r/0.300436" class="keytip" data-code="0,300436">广生堂</a></span><span id="quote_0.300436"></span>、<span id="stock_0.002932"><a href="http://quote.eastmoney.com/unify/r/0.002932" class="keytip" data-code="0,002932">明德生物</a></span><span id="quote_0.002932"></span>等多股涨逾10%。</p><center><img src="https://dfscdn.dfcfw.com/download/D24807378640860348680_w296h480.jpg" alt="Image" width="296" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>医药板块全线爆发</strong></p><p><strong>医药生物板块的431股中有411股今日股价上涨，<span id="stock_1.600056"><a href="http://quote.eastmoney.com/unify/r/1.600056" class="keytip" data-code="1,600056">中国医药</a></span><span id="quote_1.600056"></span>今日开盘即一字涨停，在近10个交易日内累积涨幅近80%。</strong>消息面上，昨日<span web="1" href="http://quote.eastmoney.com/unify/r/1.600056" class="em_stock_key_common" data-code="1,600056">中国医药</span><span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>称，3月9日与<span id="stock_106.PFE"><a href="http://quote.eastmoney.com/unify/r/106.PFE" class="keytip" data-code="106,PFE">辉瑞</a></span><span id="quote_106.PFE"></span>公司签订供货协议，将在2022年度负责<span web="1" href="http://quote.eastmoney.com/unify/r/106.PFE" class="em_stock_key_common" data-code="106,PFE">辉瑞</span>的新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装在中国大陆市场的商业运营。不过，公司今日表示预计相关业务规模占公司整体业务量比重较小，对公司近期经营业绩无重大影响。</p><p><strong>此外，受到日本盐野义新冠口服药即将投入临床治疗消息刺激，<span id="stock_0.000788"><a href="http://quote.eastmoney.com/unify/r/0.000788" class="keytip" data-code="0,000788">北大医药</a></span><span id="quote_0.000788"></span>、<span id="stock_0.002435"><a href="http://quote.eastmoney.com/unify/r/0.002435" class="keytip" data-code="0,002435">长江健康</a></span><span id="quote_0.002435"></span>今日均一字涨停。</strong></p><p><span id="Info.116.02359"><a href="http://quote.eastmoney.com/unify/r/116.02359" class="keytip" data-code="116,02359">药明康德</a></span>今日涨超9%，昨日晚间，<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>公布今年1至2月主要经营数据，其在手订单和销售收入同比增速均超过65%，创下历史新高，<span web="1" href="http://quote.eastmoney.com/unify/r/116.02359" class="em_stock_key_common" data-code="116,02359">药明康德</span>预计2022年第一季度收入同比增长将达到65%-68%。展望全年，公司收入同比增长有望达到65%-70%。</p><p><strong>业绩高增标的出炉</strong></p><p><strong>资金看好这几只</strong></p><p>目前新冠疫情仍在持续影响人类的生产和生活，随着全国多地的新增确诊病例出现，防疫仍然是生活中常态化的一部分。今年的政府工作报告提出，加大对病毒变异的研究和防范力度，加快疫苗和特效药物研发，持续做好疫苗接种工作，科学精准处置局部疫情，保持正常生产生活秩序。<strong>在医药领域中，药品、高质耗材集中采购，疫苗监管，医保支付改革等均被列入2022年发展的预期目标。</strong></p><p>实际上，医药板块在2021年经历了较大幅度的回撤，对于医药板块后续的走向，机构普遍认为，经过前期的调整，板块的负面因素得到了充分释放，投资价值凸显，估值处于历史底部区域，当下的政策背景下，产业发展快、增速快的公司，会成为市场的风口，目前正处于年报、一季报业绩披露期，高增长或超预期的公司或许能够获得市场青睐。</p><p><span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>时报·数据宝梳理，从春节后的行情表现来看，400余股平均上涨3.88%，跑赢大盘。<strong>有39股的累计上涨幅度超过20%，<span id="stock_1.603122"><a href="http://quote.eastmoney.com/unify/r/1.603122" class="keytip" data-code="1,603122">合富中国</a></span><span id="quote_1.603122"></span>、<span id="stock_0.301201"><a href="http://quote.eastmoney.com/unify/r/0.301201" class="keytip" data-code="0,301201">诚达药业</a></span><span id="quote_0.301201"></span>两只<span id="Info.3309"><a href="http://data.eastmoney.com/xg/xg/default.html" class="infokey">新股</a></span>涨幅翻倍，<span id="stock_0.300584"><a href="http://quote.eastmoney.com/unify/r/0.300584" class="keytip" data-code="0,300584">海辰药业</a></span><span id="quote_0.300584"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002435" class="em_stock_key_common" data-code="0,002435">长江健康</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.600056" class="em_stock_key_common" data-code="1,600056">中国医药</span>等股涨幅均超70%。</strong></p><p>目前，306只医药生物概念股发布了2021年业绩预告或快报，从预告下限和快报数据来看，249家上市公司在2021年实现盈利，<span id="stock_0.300122"><a href="http://quote.eastmoney.com/unify/r/0.300122" class="keytip" data-code="0,300122">智飞生物</a></span><span id="quote_0.300122"></span>、<span id="stock_1.600518"><a href="http://quote.eastmoney.com/unify/r/1.600518" class="keytip" data-code="1,600518">*ST康美</a></span><span id="quote_1.600518"></span>、<span id="stock_1.603259"><a href="http://quote.eastmoney.com/unify/r/1.603259" class="keytip" data-code="1,603259">药明康德</a></span><span id="quote_1.603259"></span>、<span id="stock_1.688298"><a href="http://quote.eastmoney.com/unify/r/1.688298" class="keytip" data-code="1,688298">东方生物</a></span><span id="quote_1.688298"></span>、<span id="stock_0.002001"><a href="http://quote.eastmoney.com/unify/r/0.002001" class="keytip" data-code="0,002001">新和成</a></span><span id="quote_0.002001"></span>的2021年归母<span id="Info.3324"><a href="http://data.eastmoney.com/bbsj/" class="infokey">净利润</a></span>额均超40亿元。<strong>184股列入绩优行列(盈利且同比呈现增长)，其中64股的业绩同比去年呈现翻倍增长。</strong><span id="stock_1.603222"><a href="http://quote.eastmoney.com/unify/r/1.603222" class="keytip" data-code="1,603222">济民医疗</a></span><span id="quote_1.603222"></span>的增幅居首，公司2021年<span id="Info.3323"><a href="http://data.eastmoney.com/bbsj/" class="infokey">营业收入</a></span>为11.07亿元，同比增长26.14%；归母净利润1.47亿元，同比增长2205.39%，公司<span id="bk_90.BK1041"><a href="http://quote.eastmoney.com/unify/r/90.BK1041" class="keytip" data-code="90,BK1041">医疗器械</a></span><span id="bkquote_90.BK1041"></span>板块业务利润实现较大幅度增长。</p><p>春节后以来，30股的<span id="Info.3314"><a href="http://data.eastmoney.com/hsgt/index.html" class="infokey">北上资金</a></span>净买入额录得正值，<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span id="stock_1.603392"><a href="http://quote.eastmoney.com/unify/r/1.603392" class="keytip" data-code="1,603392">万泰生物</a></span><span id="quote_1.603392"></span>分别获得9.32亿元和5.19亿元的北上资金加仓，<span id="stock_0.000423"><a href="http://quote.eastmoney.com/unify/r/0.000423" class="keytip" data-code="0,000423">东阿阿胶</a></span><span id="quote_0.000423"></span>、<span id="stock_0.300601"><a href="http://quote.eastmoney.com/unify/r/0.300601" class="keytip" data-code="0,300601">康泰生物</a></span><span id="quote_0.300601"></span>、<span id="stock_0.300244"><a href="http://quote.eastmoney.com/unify/r/0.300244" class="keytip" data-code="0,300244">迪安诊断</a></span><span id="quote_0.300244"></span>、<span id="stock_1.600216"><a href="http://quote.eastmoney.com/unify/r/1.600216" class="keytip" data-code="1,600216">浙江医药</a></span><span id="quote_1.600216"></span>的北上资金净买入额均超亿元。</p><p>今日医药生物板块的<span id="Info.3291"><a href="http://data.eastmoney.com/zlsj/" class="infokey">主力</a></span><span id="Info.313"><a href="http://data.eastmoney.com/zjlx/" class="infokey">净流入</a></span>额高达46.64亿元，104只医药概念股实现净流入，<span web="1" href="http://quote.eastmoney.com/unify/r/1.603259" class="em_stock_key_common" data-code="1,603259">药明康德</span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.300122" class="em_stock_key_common" data-code="0,300122">智飞生物</span>、<span id="stock_0.300363"><a href="http://quote.eastmoney.com/unify/r/0.300363" class="keytip" data-code="0,300363">博腾股份</a></span><span id="quote_0.300363"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/1.688298" class="em_stock_key_common" data-code="1,688298">东方生物</span>、<span id="Info.116.06821"><a href="http://quote.eastmoney.com/unify/r/116.06821" class="keytip" data-code="116,06821">凯莱英</a></span>、<span id="stock_0.300639"><a href="http://quote.eastmoney.com/unify/r/0.300639" class="keytip" data-code="0,300639">凯普生物</a></span><span id="quote_0.300639"></span>、<span id="stock_0.301015"><a href="http://quote.eastmoney.com/unify/r/0.301015" class="keytip" data-code="0,301015">百洋医药</a></span><span id="quote_0.301015"></span>、<span web="1" href="http://quote.eastmoney.com/unify/r/0.002001" class="em_stock_key_common" data-code="0,002001">新和成</span>等10余股的净流入额均超亿元。</p><center><img src="https://dfscdn.dfcfw.com/download/D24635752449663031579_w808h802.jpg" alt="Image" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p class="em_media">（文章来源：<span web="1" href="http://quote.eastmoney.com/unify/r/90.BK0473" class="em_stock_key_common" data-code="90,BK0473">证券</span>时报）</p>

<http://finance.eastmoney.com/news/1353,202203102304910319.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)